Repurposing pharmaceutical facilities into productive assets
The footprints of many pharmaceutical companies have changed over the past two decades. Mergers among top global players and more efficient workspaces have changed the focus of many companies toward consolidation, divestiture, and creating flexible spaces for biopharmaceutical manufacturing processes. These companies have undertaken consolidation programs to reduce their footprint, maximize building efficiency, improve workplace environments, and reduce operating costs.
Such consolidation programs often require extensive environmental remediation, abatement, decontamination, demolition, and redevelopment as pharmaceutical companies look for innovative ways to repurpose their facilities for different uses.
Finding a strategic partner to design flexibility
As a strategic partner, OBG provides support of operational needs and business strategies, and solutions from decontamination through redeveloping sites for future use. These solutions are helping companies to restore operating and inactive pharmaceutical sites with the flexibility needed to adapt to changing production processes well into the future.
Across the pharmaceutical industry, OBG has addressed more than 25 million square feet of space at hundreds of sites, from small manufacturing suites to 2,000-acre campuses.
See how the Company has helped one major pharmaceutical and healthcare company repurpose research and manufacturing space across the U.S.
Looking for more information? Contact OBG’s Bob Patullo, who brings more than 35 years of design and construction experience in the biotech, pharmaceutical, research, institutional, corporate, and infrastructure industries.